Fabtech Technologies Limited (NSE: FABTECH, BSE: 544558) shared its investor presentation alongside unaudited financial results for the quarter and nine months ended Dec. 31, 2025, highlighting higher income over the nine-month period, a strong order book, and continued dependence on Middle East markets, while margins and net profit declined year on year.
Nine-month FY26 financial performance
For the nine months ended December 2025, total income rose 32.8% year on year to ₹26,309.11 lakh, compared with ₹19,811.85 lakh in the same period last year. The growth reflected execution of turnkey engineering projects across pharmaceutical, biotech and healthcare facilities.
EBITDA declined 45.0% to ₹2,390.12 lakh, with the EBITDA margin falling to 9.08% from 21.95% a year earlier. Net profit for the period fell 48.0% to ₹1,630.23 lakh, and net profit margin declined to 6.20% from 15.83%. Earnings per share dropped to ₹4.49 from ₹9.68 in 9M FY25.
Order book and geographic exposure
Fabtech reported an order book of ₹98,305 lakh as of Nov. 3, 2025, providing medium-term revenue visibility. The company derives a large share of revenue from overseas markets. The presentation noted that 78% of revenue is generated from MENA, GCC and ECO Zone markets, reflecting strong exposure to the Middle East and Africa region.
The company operates in 62 countries, delivering start-to-finish turnkey solutions, including design, engineering, manufacturing and validation of cleanrooms, HVAC, process equipment and purified water systems. Management highlighted post-COVID investments in pharmaceutical self-reliance in the Middle East as a key growth driver.
Business model and capabilities
Fabtech positions itself as a global turnkey solutions provider for life sciences and healthcare projects. Its in-house capabilities span process equipment and containment systems, bio-clean air (cleanrooms and HVAC) and purified water systems, enabling integrated project delivery under global regulatory standards such as cGMP, WHO, EU-GMP and USFDA.
The company follows an asset-light, integrated model, with in-house manufacturing and limited third-party dependency aimed at reducing project execution risk, improving speed to market and maintaining quality consistency.
Deployment of IPO proceeds
The company disclosed the utilisation of issue proceeds during the quarter. Of the ₹23,029.65 lakh earmarked for working capital, acquisitions, general corporate purposes and issue expenses, ₹2,350.25 lakh had been utilised by the end of the quarter, primarily toward issue-related expenses and general corporate purposes. The remaining funds are earmarked mainly for working capital requirements and inorganic growth initiatives.
Operating footprint and workforce
Fabtech reported ISO-certified operations, a team of 180+ employees, including 94+ qualified engineers. The company continues to expand via subsidiaries and joint ventures, including cleanroom systems and process equipment entities across multiple geographies.
Summary
Fabtech Technologies recorded strong top-line growth in the first nine months of FY26, supported by execution of international turnkey projects and a healthy order book. However, profitability weakened year on year, with lower EBITDA and net profit margins. The company remains heavily exposed to Middle East markets and continues to invest in working capital and project execution capabilities to support growth in pharmaceutical and healthcare infrastructure projects.